These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23820407)

  • 1. Antitumor necrosis factor, infliximab, and adalimumab: use with caution in eosinophilic bowel disease.
    Furuta GT; Atkins D; Capocelli KE; de Zoeten EF; Fleischer D; Menard-Katcher C
    J Pediatr Gastroenterol Nutr; 2013 Oct; 57(4):e25. PubMed ID: 23820407
    [No Abstract]   [Full Text] [Related]  

  • 2. Authors' response.
    Turner D; Friesen C
    J Pediatr Gastroenterol Nutr; 2013 Oct; 57(4):e25-6. PubMed ID: 23820406
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-TNF, infliximab, and adalimumab can be effective in eosinophilic bowel disease.
    Turner D; Wolters VM; Russell RK; Shakhnovich V; Muise AM; Ledder O; Ngan B; Friesen C
    J Pediatr Gastroenterol Nutr; 2013 May; 56(5):492-7. PubMed ID: 23221994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor necrosis factor agents and placental transfer: relevant clinical data for rational decision-making.
    Kane S
    Clin Gastroenterol Hepatol; 2013 Mar; 11(3):293-4. PubMed ID: 23247325
    [No Abstract]   [Full Text] [Related]  

  • 5. [Patient information. Biological agents in inflammatory bowel disease].
    Van Domselaar M
    Rev Esp Enferm Dig; 2008 Dec; 100(12):798. PubMed ID: 19238770
    [No Abstract]   [Full Text] [Related]  

  • 6. [Application of TNF-alpha blocker concentration assays in the treatment of inflammatory bowel diseases].
    Sipponen T; Kolho KL
    Duodecim; 2013; 129(5):499-505. PubMed ID: 23520893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.
    Shen H; Lipka S; Katz S
    J Crohns Colitis; 2014 Aug; 8(8):898-9. PubMed ID: 24434182
    [No Abstract]   [Full Text] [Related]  

  • 8. Head-to-head trials in inflammatory bowel disease.
    Radford-Smith G
    J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():18-19. PubMed ID: 33817853
    [No Abstract]   [Full Text] [Related]  

  • 9. Psoriasis induced by anti-tumour necrosis factor therapy in patients with inflammatory bowel disease.
    Salgueiro P; Lago P; Pedroto I
    J Crohns Colitis; 2013 Sep; 7(8):e325-6. PubMed ID: 23352103
    [No Abstract]   [Full Text] [Related]  

  • 10. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
    J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
    Zelinkova Z; van der Ent C; Bruin KF; van Baalen O; Vermeulen HG; Smalbraak HJ; Ouwendijk RJ; Hoek AC; van der Werf SD; Kuipers EJ; van der Woude CJ;
    Clin Gastroenterol Hepatol; 2013 Mar; 11(3):318-21. PubMed ID: 23103819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
    Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C
    Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
    Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic.
    Licinio R; Losurdo G; Ierardi E; Di Leo A; Principi M
    Aliment Pharmacol Ther; 2015 Jun; 41(12):1302. PubMed ID: 25968153
    [No Abstract]   [Full Text] [Related]  

  • 15. Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure.
    Macaluso FS; Criscuoli V; Orlando E; Rizzuto G; Renna S; Cottone M; Orlando A
    Aliment Pharmacol Ther; 2016 May; 43(9):1019-20. PubMed ID: 27040168
    [No Abstract]   [Full Text] [Related]  

  • 16. Lipid Profile in Inflammatory Bowel Disease Patients on Anti-TNFα Therapy.
    Miranda-Bautista J; de Gracia-Fernández C; López-Ibáñez M; Barrientos M; Gallo-Moltó A; González-Arias M; González-Gil C; Díaz-Redondo A; Marín-Jiménez I; Menchén L
    Dig Dis Sci; 2015 Jul; 60(7):2130-5. PubMed ID: 25680875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic. Authors' reply.
    Gisbert JP; Chaparro M
    Aliment Pharmacol Ther; 2015 Jun; 41(12):1302-3. PubMed ID: 25968154
    [No Abstract]   [Full Text] [Related]  

  • 18. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure--authors' reply.
    Gisbert JP; Chaparro M
    Aliment Pharmacol Ther; 2016 May; 43(9):1020. PubMed ID: 27040169
    [No Abstract]   [Full Text] [Related]  

  • 20. [TNF-alpha blocking therapy in chronic inflammatory bowel disease].
    Molnár T
    Orv Hetil; 2009 Sep; 150(38):1773-9. PubMed ID: 19740722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.